香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司關於持股5%以上 股東權益變動觸及1%刻度的提示性公告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年8月20日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事 王曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han Dugan 博士、Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、 Alessandro Riva博士、 ...

一、 信息披露义务人及其一致行动人的基本信息 美股代码：ONC 百济神州有限公司 关于持股5%以上股东权益变动 触及1%刻度的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 | 信息披露义务人名称 | | | | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | --- | --- | --- | | Baker | Brothers | | Life | ☐ ☐ | 控股股东/实控人 控股股东/实控人的一致 | 不适用 | | Sciences, | 及 L.P. | 其 | 联 | 行动人 | | ☑ | | 属实体 | | | | ☑ | 其他直接持股股东 | | 二、 权益变动触及 1%刻度的基本情况 百济神州有限公司（以下简称"公司"）的子公司 BG NC 2, Ltd.于 2025 年 8 月 19 日（美国东部时间）向公司的托管公司移交 13,000,000 股公司的普通股， 用以换取相应数量的美国存托股份（每股美国存托股份相当于 13 股普通股），旨 ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 0.91% as of August 20, 2025, with mixed performance among constituent stocks [1] - Heartbeat Medical led the gains with an increase of 3.13%, while Yuandong Biological experienced the largest decline [1] - The market for the Sci-Tech Medical ETF managed by Harvest saw a turnover rate of 24.05% and a transaction volume of 62.637 million yuan, indicating active trading [3] Group 2 - The latest scale of the Sci-Tech Medical ETF reached 263 million yuan, marking a one-month high and ranking first among comparable funds [3] - The ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 6.157 million yuan, totaling 15.2382 million yuan [3] - The net value of the ETF increased by 56.59% over the past year, with the highest monthly return since inception being 23.29% [3] Group 3 - The total amount of business cooperation for innovative drugs in China is projected to reach 51.9 billion USD in 2024, with a record 1.25 billion USD upfront payment transaction between 3SBio and Pfizer in 2025 [4] - The Chinese innovative drug sector has seen a 25.02% increase year-to-date, ranking fourth among 31 industries, with a current PE ratio of 31.31 times [4] - The National Healthcare Security Administration has introduced a temporary management method for disease-based payment, promoting payment reform in the healthcare sector [4] Group 4 - As of July 31, 2025, the top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index accounted for 49.14% of the index, with leading companies including United Imaging and BeiGene [4][6] - The performance of individual stocks varied, with United Imaging down by 0.26% and BeiGene up by 0.95% [6] - Investors without stock accounts can access the Sci-Tech Medical ETF through the Harvest Sci-Tech Medical ETF linked fund [6]

Market Overview - The Hang Seng Index (HSI) closed at 24,951.48, down by 171.42 points or 0.68% as of August 19, 16:00 Eastern Time [1] - The index reached a high of 25,154.24 and a low of 24,938.43 during the trading session, with a trading volume of 39.6558 million [1] - The 52-week high for the index is 25,778.47, while the 52-week low is 17,034.99 [1] Blue-Chip Stocks Performance - Major blue-chip stocks mostly declined, with HSBC Holdings closing at HKD 99.581, up 0.54% compared to the Hong Kong close [2] - Tencent Holdings closed at HKD 588.764, down 0.63% compared to the Hong Kong close [2] Individual Stock Movements - Tencent Holdings (00700) saw a price of HKD 592.500, an increase of HKD 5.500 or 0.94%, but its ADR price was HKD 588.764, down HKD 3.736 compared to the Hong Kong close [3] - Alibaba Group (09988) closed at HKD 118.300, down HKD 0.300 or 0.25%, with an ADR price of HKD 116.979, down HKD 1.321 [3] - HSBC Holdings (00005) had a closing price of HKD 99.050, up HKD 0.600 or 0.61%, with an ADR price of HKD 99.581, up HKD 0.531 [3] - Xiaomi Group (01810) closed at HKD 52.400, down HKD 0.650 or 1.23%, with an ADR price of HKD 52.255, down HKD 0.145 [3] - AIA Group (01299) closed at HKD 74.200, down HKD 0.400 or 0.54%, with an ADR price of HKD 73.722, down HKD 0.478 [3]

Market Overview - On Monday, the three major US stock indices showed mixed results, while the Hang Seng Index ADR declined, closing at 25,129.61 points, down by 47.24 points or 0.19% compared to the Hong Kong closing [1]. Company Performance - Most large-cap blue-chip stocks experienced declines, with HSBC Holdings closing at HKD 99.979, up by 1.55% compared to the Hong Kong closing; Tencent Holdings closed at HKD 586.613, down by 0.07% [3]. - Notable stock movements include Alibaba W, which closed at HKD 118.600, up by 0.500 or 0.42%; and Xiaomi Group-W, which closed at HKD 53.050, up by 0.200 or 0.38% [4]. - Other significant performers include AIA Group, which closed at HKD 74.600, down by 0.350 or 0.47%; and JD Group-SW, which closed at HKD 124.000, up by 3.200 or 2.65% [4].

Market Overview - The Hang Seng Index (HSI) closed at 25,129.61, down by 47.24 points or 0.19% as of August 18, 16:00 Eastern Time [1] - The index experienced a trading range with a high of 25,246.78 and a low of 25,127.88, indicating a volatility of 0.47% [1] Major Blue-Chip Stocks Performance - Most large-cap stocks declined, with HSBC Holdings closing at HKD 98.450, down by HKD 1.850 or 1.84% [2] - Tencent Holdings closed at HKD 587.000, down by HKD 5.000 or 0.84%, while its ADR price was HKD 586.613, reflecting a slight decrease of 0.387 [2] - Alibaba Group (ADR) saw a slight increase, closing at HKD 118.600, up by HKD 0.500 or 0.42%, with its ADR price at HKD 118.660, up by 0.060 [2] Notable Stock Movements - Meituan-W experienced a minor decline, closing at HKD 121.500, down by HKD 0.200 or 0.16%, while its ADR price was HKD 122.218, up by 0.718 [2] - Pop Mart International's stock surged, closing at HKD 284.800, up by HKD 13.400 or 4.94%, with its ADR price at HKD 284.470, down by 0.330 [2] - JD Group saw an increase, closing at HKD 124.000, up by HKD 3.200 or 2.65%, with its ADR price at HKD 124.211, up by 0.211 [2]

Core Insights - BeiGene, Ltd. (百济神州) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecular targeted and immunotherapy drugs for cancer treatment [2] Financial Performance - As of June 30, 2025, BeiGene reported total revenue of $2.433 billion, representing a year-over-year growth of 44.73% [1] - The company's net profit attributable to shareholders was $95.59 million, showing a significant increase of 125.73% year-over-year [1] Product Portfolio - BeiGene has a comprehensive product portfolio that includes six internally developed clinical candidates, three of which are in late-stage clinical trials: zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor) [2] - The company has also obtained licenses for five drugs and investigational drugs, including three drugs (ABRAXANE, REVLIMID, and VIDAZA) exclusively licensed from Celgene that are already marketed in China, along with two investigational drugs in clinical stages [2] Company Background - Founded in Beijing in 2010, BeiGene was listed on the NASDAQ Global Select Market in February 2016 [2] - As of July 2018, the company had a global team of over 1,300 employees, showcasing its comprehensive capabilities in research, clinical development, manufacturing, and commercialization [2]

Group 1 - The Hong Kong stock market experienced a rise and then a pullback, with the Hang Seng Index reaching a new high [1] - The National Healthcare Security Administration is publishing a list of drugs that have passed preliminary review for the "2025 National Medical Insurance Directory and Commercial Insurance Innovative Drug Directory," which will enter expert review and negotiation stages [1][2] - The Hong Kong Innovative Drug Selected ETF (520690) saw a nearly 2.5% increase, with a trading volume exceeding 20 million and a turnover rate over 5%, indicating strong market interest [1] Group 2 - The dual-track policy of basic medical insurance and commercial insurance for innovative drugs signals a payment closure model, suggesting that "true innovation is easier to scale" [2] - The performance of innovative drugs is expected to be positively impacted by the dual-track payment system and significant business development opportunities, leading to a systematic revaluation of the Chinese innovative drug sector [2] - The Hang Seng Medical ETF (513060) is benefiting from the dual advantages of technology penetration and market expansion, particularly in AI healthcare and innovative drug companies [3]

Group 1 - Public funds have conducted over 3,800 research visits in the past month, with more than 150 institutions participating, indicating a strong interest in stock selection [2][3] - The average stock price increase of the companies researched by public funds reached 14.96%, significantly outperforming the market, with the top ten stocks seeing increases exceeding 73% [2] - The most favored sectors by public funds are TMT (Technology, Media, and Telecommunications) and pharmaceuticals, with 63 electronic companies and 47 pharmaceutical companies being researched extensively [3] Group 2 - The focus on AI technology is seen as a revolutionary change, with ongoing demand expected to drive growth across various industries [3] - In the pharmaceutical sector, there is an expectation of increased revenue for innovative drug companies, attracting long-term investments, with 2025 projected as a pivotal year for profitability [4] - The Chinese pharmaceutical industry is undergoing a valuation reset, with expectations of extended product life cycles and increased sales peaks due to the integration of commercial strategies [4]

Market Overview - The Hang Seng Index (HSI) closed at 25,237.96, down by 32.11 points or 0.13% on August 15 [1] - The index reached a high of 25,311.59 and a low of 25,199.63 during the trading session [1] Major Blue-Chip Stocks Performance - HSBC Holdings closed at HKD 99.966, down 0.33% from the previous close [2] - Tencent Holdings closed at HKD 591.706, down 0.05% from the previous close [2] Stock Price Movements - Tencent Holdings (00700) increased by HKD 2.00, or 0.34%, to HKD 592.00 [3] - Alibaba Group (09988) decreased by HKD 3.70, or 3.04%, to HKD 118.10 [3] - China Construction Bank (00939) fell by HKD 0.18, or 2.26%, to HKD 7.80 [3] - HSBC Holdings (00005) decreased by HKD 0.10, or 0.10%, to HKD 100.30 [3] - Xiaomi Group (01810) dropped by HKD 0.35, or 0.66%, to HKD 52.85 [3] - AIA Group (01299) fell by HKD 1.95, or 2.54%, to HKD 74.95 [3] - Meituan (03690) decreased by HKD 2.70, or 2.17%, to HKD 121.70 [3] - NetEase (099999) dropped by HKD 7.60, or 3.66%, to HKD 200.20 [3] - Hong Kong Exchanges and Clearing (00388) increased by HKD 0.20, or 0.05%, to HKD 439.40 [3] - Industrial and Commercial Bank of China (01398) fell by HKD 0.19, or 3.09%, to HKD 5.96 [3] - Ping An Insurance (02318) decreased by HKD 0.30, or 0.52%, to HKD 57.60 [3] - BYD Company (01211) dropped by HKD 1.00, or 0.88%, to HKD 112.80 [3] - Bank of China (03988) fell by HKD 0.09, or 1.98%, to HKD 4.45 [3] - Kuaishou Technology (01024) decreased by HKD 0.40, or 0.53%, to HKD 74.80 [3] - Ctrip (09961) increased by HKD 1.80, or 0.37%, to HKD 489.00 [3] - Tencent Music (01698) decreased by HKD 0.90, or 0.89%, to HKD 99.90 [3] - BeiGene (06160) increased by HKD 6.50, or 3.51%, to HKD 191.50 [3]